ESMO Congress 2024: Shaping the future of anticancer therapies

NewsGuard 100/100 Score

The ESMO Targeted Anticancer Therapies Congress 2024 is the annual multi-stakeholder meeting that focuses on the development of novel anticancer therapies and how this can transform the current knowledge and impact clinical care. This event brings together various experts in the early drug development arena, including investigators from academia, investor and regulatory bodies, as well as translational scientists.

The event will be held in Paris, France, between 26-28 February.

New this year

  • Four new special sessions will enrich this year's scientific programme, with international speakers from the pharmaceutical industry addressing methodological and regulatory challenges in the development and implementation of innovative cancer therapeutics.
    Related content: Session on 26 February, 13:45-15:15 CET; Sessions on 27 February, 11:15-12:45 CET and 13:45-15:15 CET; Session on 28 February, 13:30-15:00 CET

Programme highlights

  • The role of artificial intelligence, machine learning, and digital technology in early phase research: From uncovering new immunotherapy targets with clinical potential to unveiling new potential targeted therapies
    Related content: 1O, 2P, 4P, 5P and session on 27 February, 8:00-8:45 CET

  • Novel perspectives on antibody-drug conjugates: new targets, linkers, payloads and combination with other agents
    Related content: Session on 28 February, 09:15-10:45 CET

  • ctDNA as promising biomarker to predict the patients' response to treatment and guide experimental therapeutics in phase I trials
    Related content: 85O, 86O, Session on 27 February, 09:15-10:45 CET

Award keynote lectures

The results of more than 110 studies from various parts of the world will be presented and published online as a supplement to ESMO Open. The abstract titles can be viewed through the online programme.

Press accreditation

ESMO welcomes press representatives working for recognized press outlets interested in obtaining information and reporting on cancer issues, upon presentation of a letter of assignment and a valid press card. Press representatives are required to observe and abide by the ESMO Policy on Press Activities. To apply for press accreditation, please fill out the form available here. Requests for press accreditation should be sent by Friday, 23 February. Please be kindly informed that onsite press accreditation will not be available.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Three early-phase clinical studies show promising initial data for patients with lymphoma, gastric cancers